Jessica Hamlin, Michael Bodley, Janelle Bradley, Jacob Robbins, Kia Kokalitcheva and Madeline Shi contributed to this report.
Private markets are beginning to digest the impacts of larger-than-expected tariffs announced Wednesday as part of the Trump administration’s “Liberation Day.”
The trade actions imposed 10% tariffs on all US imports and far higher levies on major trading partners—34% on goods from China and 20% on European Union imports. Stocks plummeted Thursday in the worst trading day since 2020, with the S&P 500 dropping 4.84%.
The new tariffs add fresh uncertainty for dealmakers, who expect a chilling effect on exits and are factoring in higher inflation and recession risks. Much depends on how global trading partners will react and whether the new levies will be permanent.
IPOs on ice
The IPO window had only barely cracked and appears firmly shut for now, just a week after AI company CoreWeave was valued at $23 billion in its lukewarm Nasdaq debut.
IPO roadshows will have to wait as institutional investors assess the impact of tariffs on their portfolios. That’s easier said than done, given the complexity of both the tariff plan and the mechanics of the global supply chain.
“There’s going to be zero appetite to do acquisitions, and the IPO market might shut down,” said Sapphire Ventures president and partner Jai Das. “I don’t think companies can go public.”
Still, businesses that have been gearing up to list will be ready to go when the time is right.
“The key is to be ready to pull the trigger if stability returns, but there’s no point in charging into the canyons right now while institutions are very focused on their current positions,” said Lise Buyer, founder of IPO advisory firm Class V Group.
In the meantime, the pressure on exits will continue, which in turn will curb the ability of GPs to raise new funds and confidently deploy dry powder.
Uncertainty vs. opportunity
The uncertainty around tariffs and related macro risks are more detrimental to dealmaking than the policies themselves, according to Paul Aversano, managing director at consulting firm Alvarez & Marsal. “Uncertainty is the problem. Tariffs aren’t necessarily the problem,” he said.
Company valuations will be harder to assess, with prices subject to the projections dealmakers make for interest rates and inflation, said Brian Wheeler, a partner at law firm Foley & Lardner.
Once seen as a bargaining chip, tariffs are increasingly considered a long-term reality. If GPs feel confident that tariffs will continue—and are able to price in that risk—dealmaking should pick up. That’s due both to the large amount of dry powder available to PE firms and the opportunities that sharp changes to the markets can create.
That level of certainty remains out of reach for now, so buyers have become creative in how they structure deals to reduce risks with strategies like earn-outs, post-closing adjustments, and selling minority instead of controlling interests, Aversano said.
The ‘R’ word
Markets were spooked by the magnitude of the tariffs, which were generally far higher than expected. But they have not yet priced in a recession.
“Markets have clearly taken note but are still far from pricing in the most negative scenarios, with valuations on many equities still elevated vs. history,” wrote Janus Henderson analysts Oliver Blackbourn and Adam Hetts in a note.
Rising costs that result from tariffs will act as a brake on consumer spending and increase inflation, said Jeep Kline, Raisewell Ventures founder and former World Bank economist. That inflationary pressure would make it hard for the Federal Reserve to lower interest rates if economic conditions worsen.
“The level of investment will decrease, simply because one certainty as a fund manager in private markets is you are also competing with the cost of capital,” she said.
Learn about our editorial standards.